Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
November 21, 2024 08:19 ET
|
Biomerica, Inc.
New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
November 18, 2024 08:00 ET
|
EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
November 18, 2024 03:00 ET
|
EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
Taurex Launches Atmos: Redefining Secure and Transparent Prop Trading
November 15, 2024 09:06 ET
|
Taurex
Taurex Launches Atmos: A New Standard in Secure and Transparent Prop Trading
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
November 12, 2024 08:10 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain
October 30, 2024 08:19 ET
|
Biomerica, Inc.
Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from www.infoodsIBS.com without needing to visit a doctor’s officeWith a simple, at-home finger-prick...
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
October 22, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
Oshi Health Raises $60M Series C to Strengthen Its Position as the Category Leader for Virtual Digestive Care
October 16, 2024 08:00 ET
|
Oshi Health
Oshi Health Raises $60M Series C to Strengthen Its Position as the Category Leader for Virtual Digestive Care
Shaping the Future of Trading: Taurex Showcases Advanced Trading Solutions as Titanium Sponsor at Forex Expo Dubai 2024
October 14, 2024 02:50 ET
|
Taurex
Shaping the Future of Trading:
Taurex Showcases Advanced Trading Solutions as Titanium Sponsor at Forex Expo Dubai 2024.
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 19, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...